Pfizer
PFE
2,941 hedge funds and large institutions have $112B invested in Pfizer in 2023 Q4 according to their latest regulatory filings, with 329 funds opening new positions, 866 increasing their positions, 1,591 reducing their positions, and 270 closing their positions.
22% more first-time investments, than exits
New positions opened: 329 | Existing positions closed: 270
0% more funds holding
Funds holding: 2,929 → 2,941 (+12)
0.25% less ownership
Funds ownership: 69.25% → 68.99% (-0.25%)
14% less capital invested
Capital invested by funds: $131B → $112B (-$19B)
23% less funds holding in top 10
Funds holding in top 10: 52 → 40 (-12)
29% less call options, than puts
Call options by funds: $2.5B | Put options by funds: $3.5B
46% less repeat investments, than reductions
Existing positions increased: 866 | Existing positions reduced: 1,591
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$555M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$336M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$331M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$282M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$256M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$558M |
| 2 |
Two Sigma Advisers
New York
|
-$300M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$266M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$262M |
| 5 |
Two Sigma Investments
New York
|
-$232M |
PFE Hedge Fund Activity: Q4 2023 in Review
2,941 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2023, worth a combined $112B — down 14% from $131B a quarter earlier.
Buyers outnumbered sellers: 329 funds opened new PFE positions and 270 closed out — a net gain of 59 holders — while 866 added to existing stakes and 1,591 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $555M. The largest seller was T. Rowe Price Associates, cutting an estimated $558M.
- 2,941 institutional investors held Pfizer (PFE) as of Q4 2023, up from 2,929 in Q3 2023.
- Funds reported $112B of Pfizer stock for Q4 2023, down 14% quarter-over-quarter.
- 329 funds opened new Pfizer positions in Q4 2023 and 270 closed out, a net change of +59 holders.
- The largest Pfizer buyer in Q4 2023 was Neuberger Berman Group, an estimated $555M added.
- The largest Pfizer seller in Q4 2023 was T. Rowe Price Associates, an estimated $558M sold.
Based on aggregated 13F filings for Q4 2023.